UBS Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $45
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
Express News | Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
